FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, and concerns a liposomal drug preparation containing a polyvalent ionic preparation as an active substance with one or more dissociating groups at dissociation constant 4.5-9.5, wherein a liposome has a size of about 30-80 mm and a phospholipid bilayer has a phospholipid with a phase transition temperature above the body temperature so that the phase transition temperature of the liposome is above the body; a method of treating a tumour in a patient involving administering the above liposomal drug preparation.
EFFECT: group of inventions provides the higher therapeutic efficacy index of the liposomal preparation, especially more effective control of liposomal drug preparation recovery after targeted on the involved area, reduced loss of the drug preparation during the blood circulation of the liposomal drug preparation and more effective drug release into the target tissues.
17 cl, 21 ex, 3 dwg, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF MITOXANTHRON LIPOSOME FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMA | 2019 |
|
RU2804477C2 |
| USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME | 2021 |
|
RU2821030C1 |
| APPLICATION OF MITOXANTHONE HYDROCHLORIDE LIPOSOM FOR THE TREATMENT OF BREAST CANCER | 2021 |
|
RU2806277C1 |
| LIPOSOME HAVING INNER AQUEOUS PHASE AND CONTAINING SULPHOBUTYL ESTER CYCLODEXTRIN SALT | 2010 |
|
RU2575793C2 |
| PROLONGED RELEASE OF ANTI-INFECTIOUS AGENTS | 2006 |
|
RU2438655C2 |
| NEW LIPOSOME COMPOSITIONS | 2006 |
|
RU2454229C2 |
| STABILIZED PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN | 2016 |
|
RU2732567C2 |
| AGENT IMPROVING ANTI-CANCER EFFECT AND CONTAINING LIPOSOMAL AGENT CONTAINING OXALIPLATIN, AND ANTI-CANCER AGENT CONTAINING LIPOSOMAL AGENT | 2009 |
|
RU2492863C2 |
| COMBINATION LIPOSOMAL COMPOSITIONS FOR CANCER TREATMENT | 2012 |
|
RU2640934C2 |
| LIPOSOMAL DRUG FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASM | 2017 |
|
RU2756755C2 |
